PHU QUOC, Vietnam, May 17, 2024 /PRNewswire/ — Nestled in the vibrant southern area of Phu Quoc Island, Premier Residences Phu Quoc Emerald Bay unveils its special summer offer at the ultimate resort for families seeking fun and creativity. Here, parents and children will have the chance to truly “live in style” throughout their vacation.

Family-Friendly Accommodation

Located at Kem Beach – one of the top 100 most beautiful beaches in the world, guests staying at Premier Residences Phu Quoc Emerald Bay can truly embrace the natural beauty of the “pearl island”. The resort offers a diverse accommodation system with 752 units from rooms, suites, apartments, penthouses and villas. Particularly, apartments, penthouses or villas with open living space and private swimming pools will be the ideal choice for families looking for privacy during the vacation.

Looking over the emerald private beach, the room system here always offers outstanding views from dawn till dusk. The interior of the rooms is designed in a contemporary and elegant style with white and blue as the main color scheme, inspired by the waves and fresh ocean breezes. Whether for small families or multi-generational ones, guests will find options that perfectly cater to their needs.

The resort offers numerous picturesque spots and impressive check-in locations for travelers. The standout feature that first captures the attention of visitors at Premier Residences Phu Quoc Emerald Bay is the main building, characterized by its unique and innovative architecture, drawing inspiration from the wooden barrels used by the island’s fishermen for fermenting fish sauce.

Exciting Entertainment Activities

The resort provides a wide range of classes and workshops for both adults and children with a focus on environmentally-friendly activities such as the Little Gardener program at the Kids Club or the souvenir-making workshops using recycled materials at the Playground. These programs allow children to have fun while learning about their love for nature, the ocean and animals.

Every Saturday afternoon, the resort hosts a lively and fun pool foam party. Guests can immerse themselves in the cool, refreshing water, play with the fluffy white foam, and enjoy joyful moments with family and friends.

Staying at the resort, guests can easily visit Sunset Town, one of the most popular destinations in Phu Quoc. The entire family can admire the radiant beauty of the Kiss Bridge at dusk and capture impressive check-in photos. When night falls, families can stroll and shop at the VuiFest Night Bazaar, featuring various colorful street performances. Especially, guests should not miss the multimedia performance masterpiece “Kiss of The Sea” and the nightly fireworks display.

Summer Offer

All room rates at Premier Residences Phu Quoc Emerald Bay include tickets to the “The Kiss of The Sea” show. Upon arrival, guests simply need to contact Reception to set up their FaceID ticketing data and head to Sunset Town to enjoy this spectacular performance.

Access our media kit for the full release HERE

Contact: 

Email: HB2Q9-RE1@accor.com 

Website: https://premierresidencesphuquoc.com/

Source

Australian animal health leader adopts Veeva Vault QualityDocs and Veeva Vault Training for greater efficiency and compliance

SYDNEY, May 17, 2024 /PRNewswire/ — Troy Animal Healthcare and Veeva Systems (NYSE: VEEV) today announced Troy’s selection of Veeva Vault QualityDocs and Veeva Vault Training to simplify its compliance, content management, and data processes. Troy Animal Healthcare (Troy), the Australian-owned leader in animal healthcare and manufacturing will use Veeva Vault Quality applications to streamline and automate its operations, accelerating the development of novel drugs for animals.

“Harmonizing quality and GxP compliance processes will drive efficient quality management across our operations,” said Paul Barnett, CEO at Troy. “As the first animal health company in Australia to adopt Veeva Vault QualityDocs and Veeva Vault Training, we are introducing new standards for GxP management, compliance, and collaboration. This is a critical advancement as we continue to provide products for the unmet clinical needs in veterinary health.”

With Vault QualityDocs, Troy will modernize its GxP document control and SOP management with built-in industry best practices and standardization to ensure compliance. The company will also use Vault Training to develop and assign curriculum digitally, increasing visibility of training requirements. Using quality applications on a single cloud-based platform will increase productivity and GxP compliance while driving more effective audits and inspections.

“We are proud to partner with Troy to drive quality excellence across their operations in Australia,” said Chris Shim, general manager, Asia R&D and Quality at Veeva. “Veeva Vault Quality will provide a single source for content, streamlining quality processes and workflows to drive innovation across Troy’s animal welfare solutions.”

Vault QualityDocs and Vault Training are a part of Vault Quality Suite, bringing together quality processes, content, lab, and training management applications on a single cloud platform. To learn more, visit veeva.com/ap/VaultQuality.

About Troy Animal Healthcare 

Established 60 years ago by Australian Veterinarians, Troy Animal Healthcare is committed to delivering innovative, high quality, affordable animal healthcare solutions which meet the challenging and changing needs of veterinary professionals and animal owners. Our search for better clinical outcomes has been the source of our growth for the past 60 years and has been critical to our success. Troy prides itself on being an Australian owned business that meets the high standards of ethics and professionalism that is expected of us by the communities that we serve. Our vision is to be the largest Australian supplier of animal healthcare pharmaceuticals, and we believe that passionate, driven and innovative people are key to bringing this vision to life. For more information, visit troylab.com.au.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.

Source

YIWU, China, May 16, 2024 /PRNewswire/ — As summer arrives in the Northern Hemisphere, sun hats and cooling towels become a perfect match. Although the summer’s heat hasn’t reached its peak, the early arrival of spring in China has noticeably advanced the sales schedule for sun protection products. Numerous merchants in Yiwu have observed a spike in sales, particularly for items such as sun hats, hats, and face-kinis since February 2024. Additionally, with the growing awareness of “national fitness”, high-tech sport gear like “cooling towels” are seeing a surge in sales.

Yiwugo.com, the official website of the Yiwu Commodity Market, is the largest commodity wholesale market in the world. According to big data from Yiwugo, from March 1, 2024, to May 12, 2024, the search volume rankings for keywords such as “hats” and “sun hats” has climbed from around the 40th place to around the 15th. During this period, the number of orders related to sun hats has remained nearly the same as in 2023, but the transaction value of these orders has increased by 1.65 times. Meanwhile, from April 1, 2024, to May 12, 2024, the number of orders related to cooling towels is 1.07 times that of 2023, with a year-on-year transaction value growth of 70%.

Mr. Zheng Xiongfeng, head of Yiwu Ruwei Clothing Co., Ltd., has been engaged in sports products such as towels and neck gaiters for many years. Seven years ago, he started producing cooling towels in response to customer demand. It was during this period that Disney buyers from Japan began cooperating with Ruwei, with the company exporting approximately 4 million cooling towels to Japan annually. This year, overseas orders came even earlier, with samples being prepared for clients as early as December 2023.

“Since 2022, the trend of sports fashion has been robust in China, and cooling towels have become popular in the domestic market,” Zheng said. By the end of April, there was a noticeable a surge in domestic orders for cooling towels. Anta, a well-known Chinese sports brand, chose Ruwei as its cooling towel supplier after a thorough selection process. The partnership has endured for over two years and continues to thrive.

In recent years, most of Ruwei’s new foreign orders have come from inquiries on the Yiwugo platform. As a leading manufacturer, Ruwei maintains a stockpile of 200 tons of raw materials for cooling towels in stock and oversees every step of the production process, from yarn procurement to fabric production and product cutting. This meticulous approach ensures control over every stage and fosters trust with clients, who often become long-term customers following sample evaluations and on-site inspections.

Hats remain a perennial industry in Yiwu, and this year’s sun protection season is no exception. Ms. Lou Shuhui and her Chengwen Hats Co., Ltd. have been in the business for nearly 20 years, primarily exporting baseball caps and bucket hats to over 30 countries, with an annual output value exceeding 50 million yuan. She noted an increase in orders from overseas brands this year. The company has been collaborating with Walmart for nearly six years, with annual transactions totaling around 2 million yuan. In 2021, they stood out among suppliers for Disney’s strict quality control on custom hats and have been working with them for three years, producing nearly 2,000 hats daily.

Another notable hat manufacturer, Fu Longnv, specializes in hats with UV protection materials. Her products, known for their SPF value, have a good reputation in the domestic market and the brand TUDROFI registered in the US has gained recognition in Europe and America. Since February, her company has been exporting outdoor sun hats with anti-slip buckles in black, white, navy, grey, and khaki. Customers frequently reorder every three days, and the company is busy with inquiries from foreign companies and buyers on the Yiwugo.

Haitao Hats Co., Ltd., a merchant in the Yiwugo industry belt, specializes in exporting fashionable yarn-dyed jacquard baseball caps. With an annual output of over 1 million caps, this 20-year professional hat manufacturer excels in fabric production, shaping machines, and the selection of lining and sweatbands. Currently, they are fulfilling a custom order for nearly 20,000 hats from a client in Tehran, Iran. In addition, they are discussing future cooperation after completing a trial order of hat brims customized by a procurement group from Guangzhou.

Amidst the scorching summer sun, sun protection products and cooling towels are in full swing for the peak season. Yiwugo stands out as the optimal platform for buyers seeking a wide array of best-selling products and reliable suppliers.

Source

Exclusive 20% discounts, lucky draw prizes and memorable perks await couples

KUALA LUMPUR, Malaysia, May 16, 2024 /PRNewswire/ — Hilton properties across Malaysia are pleased to announce the Weddings at Hilton. Whether you’re planning an intimate gathering or a lavish affair, let Hilton properties in Malaysia make your special day truly unforgettable.

The festivities commence with an exclusive 20% discount on selected wedding packages, Hilton Honor bonus points as well as additional perks from selected wedding partners. For convenience and easy bookings, the online wedding sale was launched on 6^th May and will commence till 30^th May 2024. Guests are encouraged to take the opportunity to enjoy great savings on this limited time offer via visiting weddingsathilton.com 

For those looking for customized packages and arrangements, the much-anticipated KLPJ Wedding Fair awaits from May 17^th to May 19^th, Booth B85, Hall 3 at Mid-Valley Exhibition Center. From start to finish, Hilton wedding specialists ensure a stress-free stroll down the aisle. Furthermore, booking made during the wedding fair comes inclusive of perks such as a complimentary stay in the Bridal Suite, customizable menus and food tasting just to name a few. Couples will also earn double Hilton Honors Points, which can be used to redeem a honeymoon at any Hilton hotel worldwide.

Attendees at the fair will have the chance to win lucky draw prizes from exclusive vendors which include complimentary pre-wedding cinematography by Motion In Style Production, a 2-hour 360 video booth service by TagBooth Photobooth, or a studio photoshoot by Precious. Additionally, all participants, regardless of their deposit amount, will receive a goodie bag with edible gift favors, cash vouchers, promotional materials, and a chance to win a 2-tier wedding cake by Sylvia Alexa Artistry.

Participating Hilton Properties:

Hilton Kuala Lumpur
Hilton Petaling Jaya
Hilton Kuching
Hilton Kota Kinabalu
Doubletree by Hilton Kuala Lumpur
Doubletree by Hilton Putrajaya Lakeside
Doubletree by Hilton Melaka
Doubletree by Hilton Johor Bahru
Doubletree by Hilton Shah Alam i-City
Doubletree by Hilton Damai Laut Resort
Doubletree Resort by Hilton Penang
Hilton Garden Inn Puchong

Wedding Partners:

Arifah Hot Oven
Sylvia Alexa Artistry
Armadale Weddings
Precious Wedding & The Gown Atelier
Mohan’s Executives Tailors
Momento Wedding
Motion In Style
TagBooth Photobooth
Posterlite
Merry Ice Cream

Book your wedding package during this month-long celebration of love and embark on a journey that will leave cherished memories for a lifetime. For more information, visit weddingsathilton.com.

Source

SUZHOU, China and ROCKVILLE, Md., May 16, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for Poster Presentations at the 2024 European Hematology Association Hybrid Congress (EHA 2024). These posters will feature olverembatinib (HQP1351), the first and only China-approved third-generation BCL-ABL1 inhibitor; investigational lisaftoclax (APG-2575), a Bcl-2 selective inhibitor; and investigational APG-5918, an EED selective inhibitor.

The European Hematology Association (EHA) Hybrid Congress is the largest gathering of the hematology field in Europe. It showcases the most cutting-edge research and state-of-the-art innovative therapies, attracting over 10,000 clinical experts and researchers from more than 100 countries every year. This year, the EHA Hybrid Congress will take place on June 13 – 16, 2024, in Madrid, Spain.

“I am delighted to showcase the strength and progress of Ascentage Pharma in hematology at this year’s congress, especially the therapeutic potential and clinical value of its drug candidates in chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), multiple myeloma (MM), immunoglobulin light-chain (AL) amyloidosis, and anemia diseases,” said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. “We look forward to sharing the detailed results at the congress. In the future, we will continue to advance those development programs in efforts to bring more treatment options to patients around the world.”

The five studies to be presented at EHA 2024 are as follows:

• Olverembatinib

Olverembatinib Overcomes Ponatinib and Asciminib Resistance in Patients (Pts) with Heavily Pretreated Chronic Myeloid Leukemia (CML) and Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)

•    Abstract#: P722
•    Presentation Type: Poster presentation
•    Topic: Chronic myeloid leukemia – Clinical
•    Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
•    Presenting Author: Dr. Elias Jabbour, The University of Texas MD Anderson Cancer Center

Combination of Third Generation TKI Olverembatinib and Chemotherapy or Blinatumomab for New Diagnosed Adult Ph⁺ ALL Patients

•    Abstract#: P427
•    Presentation Type: Poster presentation
•    Topic: Acute lymphoblastic leukemia – Clinical
•    Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
•    Presenting Author: Junjie Chen, Nanfang Hospital, Southern Medical University

Patient Reported Outcomes in Adults with TKI-Resistant Chronic Myeloid Leukemia Receiving Olverembatinib-Therapy

•    Abstract#: P1862
•    Presentation Type: e-Poster presentation
•    Topic: Chronic myeloid leukemia – Clinical
•    Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
•    Presenting Author: Lu Yu, Peking University People’s Hospital

• Lisaftoclax

Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (Pts) with Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis

•    Abstract#: P917
•    Presentation Type: Poster presentation
•    Topic: Myeloma and other monoclonal gammopathies – Clinical
•    Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
•    Presenting Author: Dr. Sikander Ailawadhi, Mayo Clinic Florida

Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Improves Chronic Kidney Disease- (CKD)-Induced Hemoglobin (HB) Insufficiency in Preclinical Models of Anemia

•    Abstract#: P1550
•    Presentation Type: Poster presentation
•    Topic: Enzymopathies, membranopathies and other anemias
•    Date & Time: Friday June 14, 2024, 18:00 – 19:00 CEST
•    Presenting Author: Dr. Eric Liang, Ascentage Pharma Group Inc.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials, including 5 global registrational phase III studies, in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases.

Olverembatinib, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company’s first approved product, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company’s investigational drug candidates.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

Source